4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cloudbreak Pharma Inc. (2592) operates in the Biotechnology industry and is headquartered in Irvine, United States with about 61 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, 2592 reported $0M in revenue and ($68M) in net income.
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $10M | $0M | $0M |
| Operating Income (EBIT) | ($107M) | ($37M) | ($36M) | ($24M) |
| Net Income | ($68M) | ($99M) | ($129M) | ($67M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $67M | $40M | $65M | $82M |
| Total Liabilities | $6M | $392M | $328M | $227M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2592 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms